Pfizer (PFE) and Valneva (VLA FP) announce Lyme Disease vaccine candidate demonstrates strong efficacy in Phase 3 VALOR trial
- Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above
- The investigational vaccine candidate was well tolerated with no safety concerns identified at time of analysis
- Overall, results strengthen confidence in the vaccine candidate and Pfizer is planning submissions to regulatory authorities
Context
The positive results from Pfizer and Valneva's Lyme disease vaccine trial highlight a significant advancement in the pharmaceutical sector and could lead to substantial revenue opportunities for both companies. With efficacy above 70% and strong tolerability, this news not only bolsters confidence in the vaccine but also suggests Pfizer's forthcoming regulatory submissions may catalyze market interest and potentially impact stock performance in the biotech space. Overall, this could be a bullish signal for equities tied to COVID-19 and other vaccine developments.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#PFIZER INC#PFE.US#VALNEVA SE#VLA.FP#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#PFE#GLOBAL EQUITIES